This invention relates to a compound selected from resveratrol and pharmaceutically acceptable salts, esters, and conjugates thereof for use in a method of treating impaired contraction of the heart, manifest as heart failure, in the presence of ischaemic heart disease in a human subject. The invention further relates to a method of treating impaired contraction of the heart in the presence of ischaemic heart disease in a human subject with the use of resveratrol and pharmaceutically acceptable salts, esters, and conjugates thereof. In particular, the invention relates to a combination of a compound selected from resveratrol and pharmaceutically acceptable salts, esters and conjugates thereof, and perhexiline or pharmaceutically acceptable salt thereof for use in the treatment of impaired contraction of the heart, manifest as heart failure, in the presence of ischaemic heart disease in a human subject.
